Overall, the addition of oral semaglutide 7 mg or 14 mg compared favorably to the addition of sitagliptin 100 mg in patients with T2DM inadequately controlled on metformin sulfonylurea background therapy
IQVIA Payer Control Library The Bottom Line The GLP-1 market sits at the intersection of clinical innovation and patient behavior, where real-world persistence often falls short of therapeutic potential
For years, the idea of activating glucagon receptors for weight loss seemed counterintuitive since glucagon raises blood sugar
In one study, patients regained about two-thirds of the weight they had lost just one year after stopping semaglutide treatment, and their cardiometabolic risk markers (blood sugar, cholesterol, etc.) reverted toward baseline (source)
Participants were excluded if they used these drugs in the year before enrolment or had contraindications to them
Bloodwork included tests not covered by OHIP, costing another $130